Gamal El Dein Badary Amira, Bakry Rania, Rezk Khalid, Af Amine Maged, M Zahran Asmaa
Molecular Biology Research & Studies Institute, Assiut, Egypt.
South Egypt Cancer Institute, Clinical Pathology Department, Assuit, Egypt.
J Egypt Natl Canc Inst. 2025 May 23;37(1):41. doi: 10.1186/s43046-025-00287-x.
Colorectal cancer (CRC) is one of the most common tumors in the world. A recent area of study for the treatment of patients with solid tumors is anti-tumor immunity. PD-1/PD-L1 inhibitors were beneficial for cancer patients with multiple tumor types. However, their efficacy for CRC is low. Thus, there is an urgent need to explore additional co-inhibitory tools such as VISTA for CRC treatment.ObjectiveThe current study aimed to evaluate expression of VISTA on T cell subsets in patients with CRC and its correlation with other prognostic markers.Patients and methodsThe study included 31 patients with CRC and 25 healthy controls. All participants were subjected to full history taking, clinical examination, routine laboratory investigations, and flow cytometric detection of VISTA expression on T cell subsets on peripheral blood (PB). In addition to detection of VISTA expression on T cell subsets on tissue samples of both malignant CRC and normal colon tissue of the CRC patients.ResultsIn the peripheral blood, the expression of VISTA on CD4 T helper and CD8 T cytotoxic cells was significantly higher in CRC patients than the normal controls. There was no significant difference in VISTA expression on double positive T cells (CD4CD8) between the CRC patients and normal controls. In tissue samples, expression of VISTA on CD4 + T helper, CD8 + T cytotoxic, and double positive T (CD4 + CD8 +) cells in the malignant tissue of CRC patients was significantly higher than that in normal colonic tissue. Also, in CRC patients, the expression of VISTA on CD4 T helper, CD8 T cytotoxic, and double positive T cells in both malignant CRC tissue and normal colonic tissue was significantly higher than its expression PB.ConclusionThe higher expression of VISTA in CRC patients than the healthy controls and its higher levels in malignant CRC tissue and normal colonic tissue than PB of CRC patients suggest the role VISTA in the pathogenesis of CRC.
结直肠癌（CRC）是世界上最常见的肿瘤之一。实体瘤患者治疗的一个最新研究领域是抗肿瘤免疫。PD-1/PD-L1抑制剂对多种肿瘤类型的癌症患者有益。然而，它们对CRC的疗效较低。因此，迫切需要探索其他共抑制工具，如VISTA用于CRC治疗。
目的
本研究旨在评估VISTA在CRC患者T细胞亚群上的表达及其与其他预后标志物的相关性。
患者和方法
该研究纳入了31例CRC患者和25名健康对照。所有参与者均进行了全面的病史采集、临床检查、常规实验室检查以及外周血（PB）中T细胞亚群上VISTA表达的流式细胞术检测。此外，还检测了CRC患者恶性CRC组织和正常结肠组织的组织样本中T细胞亚群上的VISTA表达。
结果
在外周血中，CRC患者CD4辅助性T细胞和CD8细胞毒性T细胞上VISTA的表达明显高于正常对照。CRC患者和正常对照之间双阳性T细胞（CD4CD8）上VISTA的表达没有显著差异。在组织样本中，CRC患者恶性组织中CD4 +辅助性T细胞、CD8 +细胞毒性T细胞和双阳性T（CD4 + CD8 +）细胞上VISTA的表达明显高于正常结肠组织。此外，在CRC患者中，恶性CRC组织和正常结肠组织中CD4辅助性T细胞、CD8细胞毒性T细胞和双阳性T细胞上VISTA的表达明显高于其在PB中的表达。
结论
CRC患者中VISTA的表达高于健康对照，且在恶性CRC组织和正常结肠组织中的水平高于CRC患者的PB，这表明VISTA在CRC发病机制中的作用。
